Takeda’s Vaccine Business Aims High, Led By Former Gates Foundation Vaccine Director
This article was originally published in PharmAsia News
Established in January 2012 on the foundation of Takeda’s long-standing domestic pediatric vaccine business, the new initiative will be global in scale, building on the territorial gains from the Nycomed acquisition, and led by a seasoned player.
You may also be interested in...
GSK is transferring technology for the manufacture of its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower costs for such programs.
Since its acquisition by Takeda in 2008, Millennium has been advancing its candidates and expanding its pipeline through deals, M&A and the assumption of internal Takeda oncology products. Near-term, it is expecting EU approval of ADCETRIS, licensed from Seattle Genetics, in the second half of 2012.
Takeda Pharmaceutical Co.'s $13.7 billion purchase of privately held Nycomed International Management is undoubtedly pricey, at over three times the Swiss group's 2010 revenues. But because it satisfies a number of strategic and financial imperatives, the deal - Takeda's largest ever - may be worth the cost.